More News! 10 Dec 2018 British Company Raises €37M to Personalize Therapies with Machine Learning Genomics, a company based in Oxford, has increased the amount raised in a Series B round that will fund further development of its genomics technology for personalized medicine. The company adds a further €9M (£8M) to the round with the participation of Foresite Capital and F-Prime Capital, two renowned US life sciences investors. The previous […] December 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Oct 2018 Microsoft Signs its First Microbiome Partnership Microsoft Genomics will work with Cambridge-based Eagle Genomics to scale up its artificial intelligence platform for microbiome research. In recent years, it has become evident that the microbes that inhabit our body are key to our health. The microbiome has been linked to conditions such as diabetes, cancer, Alzheimer’s, multiple sclerosis and many more. However, large-scale studies […] October 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2018 AI Company Raises €8.6M to Find Drugs for Rare Diseases Faster and Cheaper Than Ever Cambridge-based Healx has raised $10M (€8.6M) in a Series A round to scale up its AI technology, which could significantly reduce the time and cost of developing drugs for rare diseases. Backed, among other investors, by the founder of Abcam, Healx plans to use the fundraising to double its workforce from 15 to over 30 […] July 26, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Mar 2018 AI Is Being Put to Work to Treat Parkinson’s Disease in the UK The artificial intelligence company BenevolentAI is collaborating with two UK charities to use AI to identify ideal drug candidates for treating Parkinson’s disease. BenevolentAI, Europe’s largest private AI company, is collaborating with Parkinson’s UK and The Cure Parkinson’s Trust (CPT), two UK charities, to repurpose at least three existing drugs and identify two novel drug targets […] March 28, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 5 Mar 2018 The Robots are Coming: Is AI the Future of Biotech? AI, or artificial intelligence, has taken root in biotech. In this article, we explore its newfound niches in the industry. Artificial intelligence (AI) and machine learning (ML) have become ubiquitous in tech startups, fueled largely by the increasing availability and amount of data and cheaper, more powerful computers. Now, if you are a new tech startup, […] March 5, 2018 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2018 Nestlé and AI Biotech Hunt Down Bioactive Peptides in Our Food Nuritas and Nestlé will use artificial intelligence to find bioactive peptides in the food we eat for applications including diabetes, anti-aging, and animal and plant health. Nuritas wants to revolutionize the discovery of natural active ingredients that can support and improve human health. The company uses artificial intelligence (AI) to look closely at the foods we […] February 14, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Feb 2018 New Artificial Intelligence Test for Leukemia Now Available in Europe Sophia Genetics has received a CE-IVD mark for its molecular diagnostics test, which will improve the detection of leukemia. Swiss company Sophia Genetics is a leader in the field of data-driven medicine, with its artificial intelligence (AI) technology already been used to analyze the next-generation sequencing data of over 160,000 patients’ around the world. Today, the company […] February 6, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 17 Jan 2018 €9M Round for AI Algorithms to Speed up Drug Development Owkin has raised $11M(€9M) in a Series A round to fund its artificial intelligence platform for medical research and drug discovery. Owkin, based in New York and Paris, was founded in 2016 to develop machine learning algorithms that can deal with the overabundance of information in biology to optimize the drug development process. The company […] January 17, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2018 Oxford Firm Recruits Two Partners to Build Drug Discovery AI e-Therapeutics has teamed up with AI experts Intellegens and Biorelate to improve its technology for computer-based drug discovery. Based in Oxford, e-Therapeutics has the mission of reducing the time and money it costs to develop new drugs with the help of artificial intelligence. Its platform can explore large amounts of public and private databases to […] January 16, 2018 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2017 Meet the Young CEO of a PCR Workflow Automation Company He is a young entrepreneur with a fast growing company. His software for the automation of PCR results interpretation in research laboratories has had a rocket start. Here’s his story! “I was looking for an internship for my bachelor’s degree in computer science…” His story starts like so many others, but unlike most it took […] October 2, 2017 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2017 Everyone Wants a Piece of this Scottish Biotech’s AI Evotec has doubled down on its investment in Exscientia: the German outfit just announced it has invested €15M to take a minority stake. Sanofi, GSK and Evotec have all jumped at the opportunity to work with Exscientia, a Scottish startup founded in 2012 and incubating in Dundee. Now, Evotec has gone beyond the initial immuno-oncology deal […] September 28, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2017 German Researchers’ Algorithm Can Predict New Targets for Existing Drugs An algorithm based on the brain’s self-organizing capacity has been developed in Germany that could combat the rising costs of drug development. A team at TU Dresden has pioneered an algorithm that exploits the self-organization of the brain to predict new drug targets, without the need for extra biological or molecular information. The study, published in Briefings […] September 27, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email